Salute e Benessere
Syngene International announces plans to add bioconjugation suite for end-to-end Antibody-Drug Conjugates Development
The OEB-5 rated suite will accelerate ADC development timelines by enabling both Monoclonal Antibodies (mAb) production and GMP bioconjugation at a single site, complementing Syngene's existing commercial capabilities in payload and linker manufacturing. Expected to be operational within this financial year, the conjugation facility will also support a range of advanced conjugates and related modalities. These services are further strengthened by collocated analytical and bioanalytical capabilities, ensuring seamless integration across the development lifecycle.
said he added.
plans to develop commercial-scale capabilities in the future.
Additionally, the laboratories will offer process development, analytical characterization, and scale-up for both early- and late-stage programs. This addition will further enhance Syngene's ability to serve biotech and biopharma clients seeking agile, science-driven partners for their ADC programs. It also reinforces the company's commitment to innovation and operational excellence in, ADCs, one of the fastest-growing segments with a large pipeline of molecules now entering clinical development.
Syngene will be present at , The team will be delighted to share further information about this investment and beyond.
Syngene International Ltd. (BSE: 539268, NSE: SYNGENE, ISIN: INE 398R01022) is an integrated research, development, and manufacturing services company serving the global pharmaceutical, biotechnology, nutrition, animal health, consumer goods, and specialty chemical sectors. Syngene's team of over 5,600 scientists brings both deep expertise and the capacity to deliver scientific excellence, robust data security and world class manufacturing, at speed, to improve time-to-market and lower the cost of innovation. With 2.5+ mn sq. ft of specialized discovery, development, and manufacturing facilities, Syngene works with around 400 global customers across industry segments, including biotech companies pursuing leading-edge science and multinationals such as BMS, GSK, Zoetis and Merck KGaA. For more details, visit www.syngeneintl.com. For the Company's latest Environmental, Social, and Governance (ESG) report, visit Syngene ESG Report
E: Shotorupa.ghosh@syngeneintl.com
E: Vijay.jeevanandham@syngeneintl.com
T: +44 (0) 203 735 8165 / +44 (0) 7834784764
E: a.khalifeh@defacto.co.uk
E: a.heeley@defacto.co.uk
Logo - https://mma.prnewswire.com/media/2637918/5584141/Syngene_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/syngene-international-announces-plans-to-add-bioconjugation-suite-for-end-to-end-antibody-drug-conjugates-development-302595670.html